Senzime AB announced that it has secured multiple new orders for the TetraGraph system from several German university hospitals. The orders are the result of comprehensive clinical and competitive product evaluations. When fully deployed, these hospitals are expected to generate annual recurring revenue contributing significantly to announced financial targets.

TetraGraph is the first portable electromyography (EMG)-based neuromuscular monitor on the market that is clinically validated and that meets the new clinical guidelines published by ESAIC (European Society of Anesthesiology and Intensive Care) and the ASA (American Society of Anesthesiologists). The TetraGraph system is used during surgery to accurately monitor the patient's level of neuromuscular block. This helps anesthesiologists secure the right dose of neuromuscular blocking drugs and their antagonists during surgery, as well as indicate when it is safe to allow patients to breathe again on their own.